Skip to main content
OncoTherapy Science, Inc. logo

OncoTherapy Science, Inc. — Investor Relations & Filings

Ticker · 4564 ISIN · JP3202150003 LEI · 529900CIAZCAIG781H52 T Professional, scientific and technical activities
Open in API
Filings indexed 71 across all filing types
Latest filing 2021-06-22 Governance Information
Country JP Japan
Listing T 4564

About OncoTherapy Science, Inc.

https://www.oncotherapy.co.jp/en/

OncoTherapy Science, Inc. is a biopharmaceutical company focused on the research and development of novel anti-cancer therapies. The company utilizes cancer-specific gene data and comprehensive cancer genome analysis to discover and develop molecular-targeted drugs, antibody drugs, cancer vaccines, and new immunotherapies. Its key technological focuses include liquid biopsy, neoantigen prediction, and T-cell receptor (TCR) repertoire analysis using next-generation sequencing. The company's primary objective is to develop highly effective cancer treatments with minimal adverse events and side effects for patients.

Recent filings

Filing Released Lang Actions
内部統制報告書－第20期(令和2年4月1日－令和3年3月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法). This is a specific regulatory requirement in Japan regarding the assessment of internal controls over financial reporting. It is not a full annual report (10-K), but rather a standalone regulatory filing concerning audit/internal control standards. Therefore, it fits best under the 'Audit Report / Information' (AR) category as it pertains to the assessment and audit of internal control systems.
2021-06-22 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references the Financial Instruments and Exchange Act (金融商品取引法). It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2020
2021-06-22 Japanese
有価証券報告書－第20期(令和2年4月1日－令和3年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains comprehensive financial data, including consolidated and non-consolidated financial indicators, balance sheets, and business performance summaries for the fiscal year ending March 31, 2021. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2021
2021-06-22 Japanese
四半期報告書－第20期第3四半期(令和2年10月1日－令和2年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the 20th fiscal year, covering the period from October 1, 2020, to December 31, 2020. It includes detailed financial statements, management analysis (MDA), and business status updates, which are characteristic of an Interim/Quarterly Report (IR). Q3 2020
2021-02-08 Japanese
四半期報告書－第20期第2四半期(令和2年7月1日－令和2年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the second quarter of the 20th fiscal period, covering the period from July 1, 2020, to September 30, 2020. It contains detailed financial statements, management analysis (MDA), and research and development activities. According to the definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim/Quarterly Report (IR). Q2 2020
2020-11-09 Japanese
訂正有価証券報告書－第19期(平成31年4月1日－令和2年3月31日)
Annual Report Classification · 100% confidence The document is a '訂正有価証券報告書' (Amended Securities Report) filed with the Kanto Local Finance Bureau in Japan. It follows the standard Japanese 'Yuka Shoken Hokokusho' format, which is the equivalent of the US 10-K annual report. The document includes detailed financial tables, business indicators, and XBRL data for the fiscal year ending March 31, 2020. As it is a comprehensive annual financial filing, it is classified as a 10-K. FY 2020
2020-11-09 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.